What is STANDARD BIOTOOLS INC's earnings per share (EPS)?

STANDARD BIOTOOLS INC (LAB) reported diluted earnings per share of $-0.20 for fiscal year 2025. This represents a 61.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

STANDARD BIOTOOLS INC Financials

LAB

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows STANDARD BIOTOOLS INC (LAB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

STANDARD BIOTOOLS INC has an operating margin of -129.2%, meaning the company retains $-129 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -140.1% the prior year.

Growth

STANDARD BIOTOOLS INC's revenue declined 6.2% year-over-year, from $91.0M to $85.3M. This contraction results in a growth score of 23/100.

Leverage

STANDARD BIOTOOLS INC carries a low D/E ratio of 0.34, meaning only $0.34 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 95/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 4.19, STANDARD BIOTOOLS INC holds $4.19 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 83/100.

Cash Flow

While STANDARD BIOTOOLS INC generated -$74.3M in operating cash flow, capex of $8.3M consumed most of it, leaving -$82.6M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

STANDARD BIOTOOLS INC generates a -17.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -29.4% the prior year.

Piotroski F-Score Neutral

5/9

STANDARD BIOTOOLS INC passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.99x

For every $1 of reported earnings, STANDARD BIOTOOLS INC generates $0.99 in operating cash flow (-$74.3M OCF vs -$74.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-4240.3x

STANDARD BIOTOOLS INC earns $-4240.3 in operating income for every $1 of interest expense (-$110.2M vs $26K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$85.3M

YoY-6.2%

5Y CAGR-9.2%

10Y CAGR-2.9%

STANDARD BIOTOOLS INC generated $85.3M in revenue in fiscal year 2025. This represents a decrease of 6.2% from the prior year.

EBITDA

-$101.0M

YoY+12.3%

STANDARD BIOTOOLS INC's EBITDA was -$101.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 12.3% from the prior year.

Net Income

-$74.9M

YoY+46.1%

STANDARD BIOTOOLS INC reported -$74.9M in net income in fiscal year 2025. This represents an increase of 46.1% from the prior year.

EPS (Diluted)

$-0.20

YoY+61.5%

STANDARD BIOTOOLS INC earned $-0.20 per diluted share (EPS) in fiscal year 2025. This represents an increase of 61.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$82.6M

YoY+45.6%

STANDARD BIOTOOLS INC generated -$82.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 45.6% from the prior year.

Cash & Debt

$120.9M

YoY-27.5%

5Y CAGR+12.0%

10Y CAGR+15.3%

STANDARD BIOTOOLS INC held $120.9M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

386M

YoY+2.3%

STANDARD BIOTOOLS INC had 386M shares outstanding in fiscal year 2025. This represents an increase of 2.3% from the prior year.

Margins & Returns

Gross Margin

49.9%

YoY+0.5pp

10Y CAGR-49.9pp

STANDARD BIOTOOLS INC's gross margin was 49.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.5 percentage points from the prior year.

Operating Margin

-129.2%

YoY+10.9pp

5Y CAGR-92.3pp

10Y CAGR-85.5pp

STANDARD BIOTOOLS INC's operating margin was -129.2% in fiscal year 2025, reflecting core business profitability. This is up 10.9 percentage points from the prior year.

Net Margin

-87.8%

YoY+64.8pp

5Y CAGR-49.4pp

10Y CAGR-41.3pp

STANDARD BIOTOOLS INC's net profit margin was -87.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 64.8 percentage points from the prior year.

Return on Equity

-17.6%

YoY+11.8pp

5Y CAGR+20.5pp

10Y CAGR+28.8pp

STANDARD BIOTOOLS INC's ROE was -17.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 11.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$26.0M

YoY-9.9%

5Y CAGR-6.5%

10Y CAGR-4.0%

STANDARD BIOTOOLS INC invested $26.0M in research and development in fiscal year 2025. This represents a decrease of 9.9% from the prior year.

Share Buybacks

YoY-100.0%

STANDARD BIOTOOLS INC spent $0 on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 100.0% from the prior year.

Capital Expenditures

$8.3M

YoY-0.6%

5Y CAGR-8.2%

10Y CAGR+7.6%

STANDARD BIOTOOLS INC invested $8.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 0.6% from the prior year.

LAB Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$85.3M-6.2%	$91.0M-14.4%	$106.3M+8.6%	$97.9M-25.0%	$130.6M-5.5%	$138.1M
Cost of Revenue	$42.8M-7.2%	$46.1M-17.5%	$55.9M-8.2%	$60.9M	N/A	N/A
Gross Profit	$42.5M-5.2%	$44.9M-11.0%	$50.5M+36.2%	$37.1M	N/A	N/A
R&D Expenses	$26.0M-9.9%	$28.8M+11.1%	$25.9M-30.6%	$37.4M-1.5%	$37.9M+4.1%	$36.5M
SG&A Expenses	$109.9M+6.6%	$103.1M+17.7%	$87.5M-14.4%	$102.3M+3.4%	$98.9M+1.0%	$97.9M
Operating Income	-$110.2M+13.5%	-$127.5M-66.4%	-$76.6M+34.1%	-$116.2M-72.3%	-$67.5M-32.2%	-$51.0M
Interest Expense	$26K-99.2%	$3.3M-27.4%	$4.6M+5.4%	$4.3M+13.3%	$3.8M+7.0%	$3.6M
Income Tax	-$37.9M-7088.2%	$542K+19.9%	$452K+116.0%	-$2.8M+36.0%	-$4.4M-309.2%	-$1.1M
Net Income	-$74.9M+46.1%	-$138.9M-86.0%	-$74.7M+60.7%	-$190.1M-220.9%	-$59.2M-11.7%	-$53.0M
EPS (Diluted)	$-0.20+61.5%	$-0.52	$-0.94+61.3%	$-2.43-211.5%	$-0.78-5.4%	$-0.74

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$3.2M-83.5%	$19.6M-10.2%	$21.8M-46.7%	$40.8M+4483.7%	$890K-96.0%	$22.1M-1.8%	$22.5M-50.6%	$45.5M
Cost of Revenue	$532K-94.7%	$10.1M-9.6%	$11.1M-47.1%	$21.1M+681.2%	$2.7M-72.9%	$10.0M-17.8%	$12.1M-43.2%	$21.4M
Gross Profit	$2.7M-71.6%	$9.5M-10.8%	$10.6M-46.2%	$19.7M+1193.7%	-$1.8M-114.9%	$12.1M+16.9%	$10.4M-57.1%	$24.2M
R&D Expenses	$2.1M-67.3%	$6.4M+2.2%	$6.2M-45.1%	$11.3M+950.5%	-$1.3M-119.2%	$6.9M-4.2%	$7.2M-54.7%	$16.0M
SG&A Expenses	$16.5M-38.1%	$26.6M-5.4%	$28.1M-27.4%	$38.7M+470.1%	$6.8M-72.3%	$24.5M-1.6%	$24.9M-47.0%	$46.9M
Operating Income	-$18.6M+43.4%	-$32.9M-28.2%	-$25.7M+22.1%	-$33.0M-218.8%	-$10.3M+61.3%	-$26.7M+11.8%	-$30.3M+49.7%	-$60.2M
Interest Expense	$5K-50.0%	$10K+11.1%	$9K+350.0%	$2K-99.7%	$572K-32.9%	$853K-0.6%	$858K-16.9%	$1.0M
Income Tax	-$35.9M-2852.3%	-$1.2M-99.7%	-$609K-303.3%	-$151K-158.8%	$257K+117.8%	$118K+202.6%	$39K-69.5%	$128K
Net Income	$19.3M+155.6%	-$34.7M-3.7%	-$33.5M-28.5%	-$26.0M+23.6%	-$34.1M-26.5%	-$26.9M+41.1%	-$45.7M-42.2%	-$32.2M
EPS (Diluted)	N/A	$-0.090.0%	$-0.09-28.6%	$-0.07	N/A	$-0.07+41.7%	$-0.12+55.6%	$-0.27

LAB Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$567.8M-7.3%	$612.3M+89.5%	$323.1M-17.2%	$390.3M+41.8%	$275.2M-15.3%	$324.8M
Current Assets	$454.3M+20.9%	$375.9M+137.6%	$158.2M-24.2%	$208.8M+189.8%	$72.1M-38.8%	$117.7M
Cash & Equivalents	$120.9M-27.5%	$166.7M+222.5%	$51.7M-36.4%	$81.3M+185.8%	$28.5M-58.5%	$68.5M
Inventory	$20.0M-3.7%	$20.7M+1.0%	$20.5M-4.4%	$21.5M+3.1%	$20.8M+5.8%	$19.7M
Accounts Receivable	$13.4M-8.9%	$14.7M-25.0%	$19.7M+13.8%	$17.3M-5.7%	$18.3M-27.9%	$25.4M
Goodwill	N/A	$111.3M+4.7%	$106.3M+0.1%	$106.3M-0.1%	$106.4M-0.2%	$106.6M
Total Liabilities	$143.5M+2.0%	$140.6M-70.2%	$471.1M-0.1%	$471.8M+161.2%	$180.6M-2.7%	$185.7M
Current Liabilities	$108.3M+64.4%	$65.9M-39.7%	$109.3M+151.7%	$43.4M-12.4%	$49.6M-8.6%	$54.2M
Long-Term Debt	N/A	$299K-99.5%	$63.5M-2.1%	$64.9M	N/A	N/A
Total Equity	$424.3M-10.1%	$471.7M+418.6%	-$148.1M-81.7%	-$81.5M-186.1%	$94.6M-32.0%	$139.1M
Retained Earnings	-$1.3B-6.3%	-$1.2B-18.5%	-$1.0B-8.1%	-$926.1M-25.8%	-$736.0M-8.8%	-$676.8M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$567.8M+5.2%	$539.6M-3.1%	$557.0M-3.9%	$579.6M-5.3%	$612.3M-10.2%	$681.5M-3.8%	$708.7M-8.9%	$777.7M
Current Assets	$454.3M-3.8%	$472.4M-6.6%	$506.0M+47.1%	$344.0M-8.5%	$375.9M-17.1%	$453.6M-5.5%	$480.0M-12.3%	$547.6M
Cash & Equivalents	$120.9M-6.6%	$129.4M-18.4%	$158.6M+5.1%	$150.9M-9.5%	$166.7M-20.8%	$210.6M-21.9%	$269.8M-6.0%	$287.1M
Inventory	$20.0M-21.4%	$25.4M+5.2%	$24.2M-42.6%	$42.1M+103.1%	$20.7M-51.4%	$42.6M+0.1%	$42.6M+5.6%	$40.4M
Accounts Receivable	$13.4M-0.8%	$13.5M-7.4%	$14.6M-58.8%	$35.5M+140.7%	$14.7M-58.3%	$35.3M+8.9%	$32.4M-9.9%	$36.0M
Goodwill	N/A	N/A	N/A	$111.7M+0.4%	$111.3M+4.7%	$106.3M+0.1%	$106.3M0.0%	$106.3M
Total Liabilities	$143.5M+2.5%	$140.0M+5.7%	$132.4M+5.9%	$125.0M-11.1%	$140.6M-26.8%	$192.2M-3.2%	$198.5M-0.9%	$200.4M
Current Liabilities	$108.3M+0.3%	$108.0M+10.1%	$98.0M+74.3%	$56.2M-14.7%	$65.9M-45.4%	$120.6M-2.6%	$123.8M+1.9%	$121.6M
Long-Term Debt	N/A	N/A	N/A	N/A	$299K-99.5%	$55.2M+0.2%	$55.1M+0.2%	$55.0M
Total Equity	$424.3M+6.2%	$399.7M-5.9%	$424.5M-6.6%	$454.6M-3.6%	$471.7M-3.6%	$489.3M-4.1%	$510.3M-11.6%	$577.3M
Retained Earnings	-$1.3B+1.5%	-$1.3B-2.8%	-$1.2B-2.8%	-$1.2B-2.2%	-$1.2B-3.0%	-$1.2B-2.4%	-$1.1B-4.2%	-$1.1B

LAB Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$74.3M+48.2%	-$143.5M-231.4%	-$43.3M+51.6%	-$89.4M-102.8%	-$44.1M-185.8%	-$15.4M
Capital Expenditures	$8.3M-0.6%	$8.4M+195.1%	$2.8M-26.0%	$3.8M-71.2%	$13.3M+4.3%	$12.7M
Free Cash Flow	-$82.6M+45.6%	-$151.8M-229.2%	-$46.1M+50.5%	-$93.2M-62.6%	-$57.3M-103.8%	-$28.1M
Investing Cash Flow	$27.4M-92.5%	$363.2M+1694.6%	$20.2M+123.0%	-$88.1M-637.7%	-$11.9M-129.9%	$40.0M
Financing Cash Flow	$570K+100.6%	-$102.6M-1407.1%	-$6.8M-103.0%	$230.8M+1345.9%	$16.0M-23.5%	$20.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0-100.0%	$40.5M+647.9%	$5.4M+861.6%	$563K	$0	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$1.2M+94.6%	-$22.2M-7.4%	-$20.7M+31.8%	-$30.3M-115.4%	-$14.1M+49.6%	-$27.9M+28.6%	-$39.0M+37.5%	-$62.5M
Capital Expenditures	$476K-46.3%	$886K-53.0%	$1.9M-62.7%	$5.1M+49.4%	$3.4M+50.0%	$2.3M+16.4%	$1.9M+148.0%	$781K
Free Cash Flow	-$1.7M+92.8%	-$23.1M-2.4%	-$22.6M+36.2%	-$35.3M-102.6%	-$17.4M+42.1%	-$30.1M+26.5%	-$41.0M+35.2%	-$63.3M
Investing Cash Flow	-$8.0M-20.3%	-$6.7M-124.3%	$27.5M+88.1%	$14.6M-43.2%	$25.7M+183.3%	-$30.9M-161.5%	$50.3M-84.2%	$318.1M
Financing Cash Flow	$620K+653.6%	-$112K-203.7%	$108K+334.8%	-$46K+99.9%	-$54.5M-2725900.0%	-$2K+100.0%	-$28.4M-43.7%	-$19.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0	$0	$0	$0	$0	$0-100.0%	$29.4M+166.4%	$11.1M

LAB Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	49.9%+0.5pp	49.3%+1.9pp	47.4%+9.6pp	37.8%	N/A	N/A
Operating Margin	-129.2%+10.9pp	-140.1%-68.0pp	-72.0%+46.6pp	-118.6%-67.0pp	-51.7%-14.7pp	-36.9%
Net Margin	-87.8%+64.8pp	-152.6%-82.4pp	-70.2%+123.9pp	-194.1%-148.7pp	-45.4%-7.0pp	-38.4%
Return on Equity	-17.6%+11.8pp	-29.4%	N/A	N/A	-62.6%-24.5pp	-38.1%
Return on Assets	-13.2%+9.5pp	-22.7%+0.4pp	-23.1%+25.6pp	-48.7%-27.2pp	-21.5%-5.2pp	-16.3%
Current Ratio	4.19-1.5	5.70+4.3	1.45-3.4	4.81+3.4	1.45-0.7	2.17
Debt-to-Equity	0.34+0.3	0.00+0.4	-0.43+0.4	-0.80-2.7	1.91+0.6	1.34
FCF Margin	-96.9%+70.0pp	-166.8%-123.4pp	-43.4%+51.8pp	-95.2%-51.2pp	-43.9%-23.5pp	-20.4%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	83.5%+35.0pp	48.5%-0.3pp	48.8%+0.5pp	48.4%+251.2pp	-202.8%-257.7pp	54.9%+8.8pp	46.1%-7.0pp	53.1%
Operating Margin	-578.6%-410.2pp	-168.5%-50.4pp	-118.1%-37.3pp	-80.8%+1081.3pp	-1162.1%-1041.2pp	-120.9%+13.6pp	-134.5%-2.4pp	-132.1%
Net Margin	598.5%+775.9pp	-177.4%-23.7pp	-153.8%-89.9pp	-63.8%+3764.5pp	-3828.3%-3706.3pp	-122.0%+81.3pp	-203.3%-132.7pp	-70.6%
Return on Equity	4.5%+13.2pp	-8.7%-0.8pp	-7.9%-2.1pp	-5.7%+1.5pp	-7.2%-1.7pp	-5.5%+3.4pp	-9.0%-3.4pp	-5.6%
Return on Assets	3.4%+9.8pp	-6.4%-0.4pp	-6.0%-1.5pp	-4.5%+1.1pp	-5.6%-1.6pp	-4.0%+2.5pp	-6.5%-2.3pp	-4.1%
Current Ratio	4.19-0.2	4.38-0.8	5.16-1.0	6.12+0.4	5.70+1.9	3.76-0.1	3.88-0.6	4.50
Debt-to-Equity	0.34-0.0	0.35+0.0	0.31+0.0	0.28+0.3	0.00-0.1	0.110.0	0.11+0.0	0.10
FCF Margin	-51.7%+66.4pp	-118.1%-14.5pp	-103.6%-17.0pp	-86.6%+1873.0pp	-1959.7%-1823.3pp	-136.4%+45.8pp	-182.2%-43.3pp	-138.9%

Similar Companies

ZIMVIE INC ZIMV

$535.7M

Cytek Biosciences, Inc. CTKB

$599.0M

Bioventus Inc. BVS

$615.7M

Orthopedia KIDS

$404.7M

Avanos Medical AVNS

$647.4M

Frequently Asked Questions

What is STANDARD BIOTOOLS INC's annual revenue?

STANDARD BIOTOOLS INC (LAB) reported $85.3M in total revenue for fiscal year 2025. This represents a -6.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is STANDARD BIOTOOLS INC's revenue growing?

STANDARD BIOTOOLS INC (LAB) revenue declined by 6.2% year-over-year, from $91.0M to $85.3M in fiscal year 2025.

Is STANDARD BIOTOOLS INC profitable?

No, STANDARD BIOTOOLS INC (LAB) reported a net income of -$74.9M in fiscal year 2025, with a net profit margin of -87.8%.

What is STANDARD BIOTOOLS INC's EBITDA?

STANDARD BIOTOOLS INC (LAB) had EBITDA of -$101.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is STANDARD BIOTOOLS INC's gross margin?

STANDARD BIOTOOLS INC (LAB) had a gross margin of 49.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is STANDARD BIOTOOLS INC's operating margin?

STANDARD BIOTOOLS INC (LAB) had an operating margin of -129.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is STANDARD BIOTOOLS INC's net profit margin?

STANDARD BIOTOOLS INC (LAB) had a net profit margin of -87.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is STANDARD BIOTOOLS INC's return on equity (ROE)?

STANDARD BIOTOOLS INC (LAB) has a return on equity of -17.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is STANDARD BIOTOOLS INC's free cash flow?

STANDARD BIOTOOLS INC (LAB) generated -$82.6M in free cash flow during fiscal year 2025. This represents a 45.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is STANDARD BIOTOOLS INC's operating cash flow?

STANDARD BIOTOOLS INC (LAB) generated -$74.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are STANDARD BIOTOOLS INC's total assets?

STANDARD BIOTOOLS INC (LAB) had $567.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are STANDARD BIOTOOLS INC's capital expenditures?

STANDARD BIOTOOLS INC (LAB) invested $8.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does STANDARD BIOTOOLS INC spend on research and development?

STANDARD BIOTOOLS INC (LAB) invested $26.0M in research and development during fiscal year 2025.

How many shares does STANDARD BIOTOOLS INC have outstanding?

STANDARD BIOTOOLS INC (LAB) had 386M shares outstanding as of fiscal year 2025.

What is STANDARD BIOTOOLS INC's current ratio?

STANDARD BIOTOOLS INC (LAB) had a current ratio of 4.19 as of fiscal year 2025, which is generally considered healthy.

What is STANDARD BIOTOOLS INC's debt-to-equity ratio?

STANDARD BIOTOOLS INC (LAB) had a debt-to-equity ratio of 0.34 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is STANDARD BIOTOOLS INC's return on assets (ROA)?

STANDARD BIOTOOLS INC (LAB) had a return on assets of -13.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is STANDARD BIOTOOLS INC's cash runway?

Based on fiscal year 2025 data, STANDARD BIOTOOLS INC (LAB) had $120.9M in cash against an annual operating cash burn of $74.3M. This gives an estimated cash runway of approximately 20 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is STANDARD BIOTOOLS INC's Piotroski F-Score?

STANDARD BIOTOOLS INC (LAB) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are STANDARD BIOTOOLS INC's earnings high quality?

STANDARD BIOTOOLS INC (LAB) has an earnings quality ratio of 0.99x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can STANDARD BIOTOOLS INC cover its interest payments?

STANDARD BIOTOOLS INC (LAB) has an interest coverage ratio of -4240.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is STANDARD BIOTOOLS INC?

STANDARD BIOTOOLS INC (LAB) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.